Scientists have made significant strides in harnessing the body's immune cells to treat liquid tumors, but solid tumors have proven more challenging. A recent study by Stanford Medicine researchers and collaborators introduces a novel cell therapy that could revolutionize the treatment of solid tumors. The focus is on supercharging natural killer cells, which are known for their ability to immediately recognize and destroy abnormal cells, into a specialized form that can reside within tissues and target tumor cells effectively.
The study's lead authors, John Sunwoo, Nina Horowitz, Imran Mohammad, and June Ho Shin, have discovered a method to transform natural killer cells into tissue-resident cells that can infiltrate solid tumors more effectively. This breakthrough is significant because it addresses the challenge of solid tumors' resistance to immune cells due to their tough environment and immune-suppressive signals. The research found that a specific cellular signal, TGF-b, plays a crucial role in transforming natural killer cells into tissue-resident cells with potent anti-tumor activity.
The study revealed that a balanced amount of TGF-b is essential; too little results in sluggish killers, while too much leads to inhibited and dysfunctional cells. The researchers identified a 'Goldilocks' recipe for TGF-b presentation, where a fleeting amount of active TGF-b from short-lived human epithelial tumor cells activates the natural killer cells. This activation requires direct contact with the tumor cells, indicating the involvement of other activation signals.
The team's findings demonstrate the potential of these supercharged natural killer cells in controlling tumor growth. When combined with cetuximab, a monoclonal antibody treatment, the therapy significantly suppressed tumors in mice, outperforming either treatment alone. The combination therapy showed no apparent adverse effects, making it a promising candidate for further development.
The study's implications are far-reaching. The researchers have developed a scalable method to produce these supercharged natural killer cells, potentially making cell therapy more accessible and cost-effective. The cells can be cryopreserved and administered to various patients, eliminating the need for personalized treatments. This approach could revolutionize the treatment of solid tumors, offering a more efficient and widely available solution.
The research team's next steps include a Phase I clinical trial of the combination therapy in patients with advanced squamous cell carcinoma, which could commence by the end of the year, pending FDA approval. The study's success highlights the potential of natural killer cell immunotherapy and opens up new avenues for cancer treatment, offering hope for patients with solid tumors.
